• Pauline Muller, Fabien Mitri, Ambre Houlle, Pierre-Olivier Vidal, Guillaume Gasperini, Nicolas Cazes, and Aurélien Renard.
• Emergency Department, Hôpital d'Instruction des Armées Sainte Anne, 2 Boulevard Sainte Anne, BP 600, 83000 Toulon, France.
• Am J Emerg Med. 2022 Jul 1; 57: 39-41.

IntroductionThe S100ß protein (PS100ß) is a biomarker, which has demonstrated its importance in diagnoses ruling out intracranial hemorrhages in people with light head traumas This study aims to evaluate if the PS100ß presents an interest in the diagnostic strategy for subarachnoid hemorrhages (SAH).MethodsProspective non-randomized multicentric study in three hospitals from October 2018 to January 2020. Every patient who came into the emergency department for an intense non-traumatic headache lasting less than 3 h received an PS100ß assay and a non-injected head computed tomography (CT) scan. The primary endpoint was the number of patients with a diagnosis of SAH on the head CT scan with a PS100ß level of under 0.10 μg/L.Results60 patients were included and five patients had a SAH. Four patients had an SAH with a PS100ß level lower than 0.10 μg/L and one patient had an SAH with a PS100ß level higher than 0.10 μg/L. The negative predictive value for the PS100ß with a discriminating threshold less than or equal to 0,10 μg/L in the diagnosis ruling out SAH was 93% [IC 95%: 0,86-1].ConclusionS100ß protein assay with a discriminating threshold of 0,10 μg/L does not demonstrate any interest in the diagnostic strategy for non-traumatic SAH.Copyright © 2022 Elsevier Inc. All rights reserved.

10 keywords...

hide…